Breaking down the barriers to gastrointestinal testing

Lifestyle image of family

Despite the importance of early detection for colon cancer, inflammatory bowel disease, and other gastrointestinal conditions, many patients are resistant to testing due to concerns with the preparation and procedures involved with these vital screenings.

Recognizing these barriers, Quest Diagnostics offers an extensive menu of minimal-prep testing that preempts patient hesitation while delivering reliable results. These patient-friendly options—combined with the medical expertise of our infectious disease and gastrointestinal pathology teams and world-class turnaround times—make for a winning combination.

Keeping current with colorectal screening guidelines

The prevalence of digestive diseases has a significant impact in the United States, with more than 60 million Americans diagnosed each year. These conditions lead to more hospitalizations than any other disease state and represent the third-highest economic loss of all illnesses. Given the complexity of digestive diseases and the subtle presentation of symptoms, early and accurate detection is essential.1

When the American Cancer Society lowered its colorectal cancer screening age guideline from 50 to 45 for average-risk patients, an estimated 21 million people in the U.S. became newly eligible for screenings. Options include visual exams, such as a colonoscopy, and stool-based tests. Stool-based screenings are required more frequently than visual exams and should always be followed by a colonoscopy if results are abnormal. 
 

Working with a microscope

Learn more about Quest colorectal screening at QuestInSureONE.com

A comprehensive range of testing


The power of Quest

References

  1. GI Alliance. Digestive disease continues to rise among Americans. February 23, 2021. Accessed August 18, 2021. https://gialliance.com/digestive-disease-continues-to-rise-among-americans/
  2. NCI Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: colorectal cancer. Survival statistics: 5-year relative survival. Accessed July 31, 2020. https://seer.cancer.gov/statfacts/html/colorect.html
  3. Savige J, Dimech W, Fritzler M, et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol. 2003;120(3):312-318. doi:10.1309/WAEP-ADW0-K4LP-UHFN
  4. Shane L, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65(12):1963-1973. doi:10.1093/cid/cix959